Global pharmaceutical company Lupin Limited has entered into an exclusive licensing agreement with U.S.-based biosimilar specialist Valorum Biologics for the commercialization of its biosimilar Armlupeg™ (pegfilgrastim-unne) in the United States.

Under the agreement, Valorum will handle the commercialization and distribution of Armlupeg in the U.S., while Lupin will remain responsible for the manufacturing and supply of the product. Lupin will receive an upfront licensing fee along with royalty payments based on net sales.

Spiro Gavaris, President – U.S. Generics at Lupin, said the partnership will enhance access to affordable treatment options for chemotherapy patients and strengthen Lupin’s presence in the U.S. biosimilars market.

“This collaboration aligns with our mission to make high-quality biosimilars more accessible and improves patient outcomes,” he said.

Par S. Hyare, CEO of Valorum, said the company is poised to capture meaningful market share through its commercial capabilities.

“We look forward to providing another option for healthcare providers and patients, expanding access to an important oncology supportive care treatment,” he added.

Pegfilgrastim-unne is used to reduce the duration of neutropenia and the risk of febrile neutropenia in patients undergoing chemotherapy.